Fu Zheng, Liu Yang, Yang Hui, Xiong Weiwei, Yin Xue, Fang Weifang, Li Xiuting, Wei Xixiang, Hu Jianzhang
Department of Ophthalmology, Fujian Medical University Union Hospital Fuzhou 350005, Fujian, China.
Department of Ophthalmology, Children's Hospital of Fudan University (Xiamen Hospital) Xiamen 361006, Fujian, China.
Am J Cancer Res. 2025 May 25;15(5):2332-2337. doi: 10.62347/GVHN8345. eCollection 2025.
This study aimed to summarize the clinical and genetic characteristics of retinoblastoma associated with newly identified RB1 gene mutations. We retrospectively analyzed 15 pediatric patients diagnosed with retinoblastoma caused by RB1 mutations. A total of 25 affected eyes were examined (8 males, 7 females). The age at diagnosis ranged from 7 to 36 months (mean 16.00 ± 8.61 months). Bilateral involvement was observed in 10 patients, and unilateral in 5. Thirteen patients presented with leukocoria, while 2 were diagnosed during routine physical examinations due to vision loss. None of the patients had a family history of retinoblastoma. Whole-exome sequencing revealed heterozygous RB1 mutations in 14 cases and a mosaic mutation in one case. Five novel mutations not previously reported in the literature were identified: c.608-1G>A, c.1818T>A, c.962dupA, c.2086A>T, and c.574A>T. All patients received treatment, including intra-arterial chemotherapy, cryotherapy, photocoagulation, systemic chemotherapy, and/or enucleation. The follow-up duration ranged from 12 to 132 months, with a mean of 39.20 ± 24.07 months. Genetic testing remains a valuable tool for confirming RB1 mutations. Expanding the RB1 mutation spectrum may facilitate early diagnosis, personalized treatment, and informed genetic counseling for affected children.
本研究旨在总结与新发现的RB1基因突变相关的视网膜母细胞瘤的临床和遗传特征。我们回顾性分析了15例诊断为由RB1突变引起的视网膜母细胞瘤的儿科患者。共检查了25只患眼(8例男性,7例女性)。诊断时的年龄范围为7至36个月(平均16.00±8.61个月)。10例患者为双侧受累,5例为单侧受累。13例患者表现为白瞳症,2例因视力丧失在常规体检时被诊断。所有患者均无视网膜母细胞瘤家族史。全外显子测序在14例中发现杂合性RB1突变,1例为嵌合突变。鉴定出5个文献中未曾报道过的新突变:c.608-1G>A、c.1818T>A、c.962dupA、c.2086A>T和c.574A>T。所有患者均接受了治疗,包括动脉内化疗、冷冻疗法、光凝治疗、全身化疗和/或眼球摘除术。随访时间为12至132个月,平均为39.20±24.07个月。基因检测仍然是确认RB1突变的重要工具。扩大RB1突变谱可能有助于对患病儿童进行早期诊断、个性化治疗和提供充分的遗传咨询。